Clinical significance of prognostic and predictive markers in colorectal cancer

Pharmacogenomics Journal

Volumn 2, Issue 4, 2002, Pages 209-216

  Longley, D B ^a   McDermott, U ^a   Johnston, P G ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 ETHYNYLURACIL; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOOXYGENASE 2 INHIBITOR; CYTOTOXIC AGENT; FLUOROURACIL; FOLIC ACID ANTAGONIST; FOLINIC ACID; GEFITINIB; IRINOTECAN; METHOTREXATE; OXALIPLATIN; PLATINUM DERIVATIVE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN P53; RALTITREXED; SOMATOSTATIN DERIVATIVE; THYMIDYLATE SYNTHASE; VASCULOTROPIN ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CHROMOSOME 17P; CHROMOSOME 18Q; CHROMOSOME 8P; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; MICROSATELLITE INSTABILITY; MULTICENTER STUDY; ONCOGENE C MYC; ONCOGENE K RAS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS;

ANIMALS; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; GENETIC MARKERS; HUMANS; MICROSATELLITE REPEATS; ONCOGENES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0036047398     PISSN: 1470269X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500124     Document Type: Article

References (73)

1. A genetic model for colorectal tumorigenesis
2. Colorectal cancer biology: Clinical implications
3. Cancer p53, guardian of the genome
4. The p53 gene in breast cancer: Prognostic value of complementary DNA sequencing versus immunohistochemistry
5. Bcl-2 protein expression: Association with p53 and prognosis in colorectal cancer
6. Cytoplasmic accumulation of p53 protein: An independent prognostic indicator in colorectal adenocarcinomas
7. p53 alterations are associated with improved prognosis in distal colonic carcinomas
8. Molecular predictors of survival after adjuvant chemotherapy for colon cancer
9. Investigation of the prognostic and predictive value of thymidylate synthase, p53 and Ki-67 in patients with locally advanced colon cancer
10. Prognostic value of p53 genetic changes in colorectal cancer
11. Disruption of p53 in human cancer cells alters the responses to therapeutic agents
12. The role of thymidylate synthase induction in modulating p53 regulated gene expression in response to 5-fluorouracil and antifolates
13. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: A Southwest Oncology Group study
14. p53 gene mutation, microsatellite instability and adjuvant chemotherapy: Impact on survival of 388 patients with Dukes' C colon carcinoma
15. Current status of adjuvant chemotherapy for colorectal cancer. Can molecular markers play a role in predicting prognosis?
16. Allelic loss of chromosome 18q and prognosis in colorectal cancer
17. Molecular predictors of survival after adjuvant chemotherapy for colon cancer
18. Deleted in Colorectal Cancer (DCC) encodes a netrin receptor
19. The Smads
20. Smad4 (DPC4)-a potent tumour suppressor?
21. Suppression of tumorigenicity and invasiveness of colon carcinoma cells by introduction of normal chromosome 8p12-pter
22. Loss of heterozygosity in 8p is associated with microinvasion in colorectal carcinoma
23. Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers
24. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer
25. P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma
26. Ki-ras mutations and prognosis in colorectal cancer
27. Ki-ras mutation type and the survival benefit from adjuvant chemotherapy in Dukes' C colorectal cancer
28. Farnesyl transferase inhibitors: A novel targeted therapy for cancer
29. Deregulation of c-myc gene expression in human colon carcinoma is not accompanied by amplification or rearrangement of the gene
30. c-myc/p53 interaction determines sensitivity of human colon carcinoma cells to 5-fluorouracil in vitro and in vivo
31. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors
32. Fluoropyrimidines as antifolate drugs
33. Capecitabine: A novel agent for the treatment of solid tumors
34. Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma
35. Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines
36. p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: An analysis of response and survival
37. Thymidylate synthase expression in colorectal cancer: A prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy
38. Immunohistochemically detected thymidylate synthase in colorectal cancer: An independent prognostic factor of survival
39. Thymidylate synthase pharmacogenomics in colorectal cancer
40. Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia
41. Thymidylate synthase gene expression in primary colorectal cancer and metastatic sites
42. Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma
43. Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy
44. Increased cytotoxicity and bystander effect of 5-fluorouracil and 5-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase
45. High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil
46. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma
47. Severe 5-fluorouracil toxicity in a patient with decreased dithydropyrimidine dehydrogenase activity
48. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase
49. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts
50. Raltitrexed (Tomudex) a highly polyglutamatable antifolate thymidylate synthase inhibitor
51. Raltitrexed (Tomudex) vs 5-fluorouracil leucovorin (5-FU + LV) in patients with advanced colorectal cancer (ACC): Results of a randomised multicenter North American trial
52. Characterization of a thymidylate synthase (TS)-inducible cell line: A model system for studying sensitivity to TS- and non-TS-targeted chemotherapies
53. Resistance to tomudex (ZD1694): Multifactorial in human breast and colon carcinoma cell lines
54. Activity of MTA in patients with advanced colorectal cancer-results from a phase II study
55. Topoisomerase-I inhibitor SN-38 can induce DNA damage and chromosomal aberrations independent from DNA synthesis
56. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma
57. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial
58. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
59. Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen
60. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells
61. The role of DNA mismatch repair in platinum drug resistance
62. Oxaliplatin: Mechanism of action and antineoplastic activity
63. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer
64. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy
65. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy
66. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
67. Vascular endothelial growth factor expression, S-phase fraction and thymidylate synthase quantitation in node-positive colon cancer: Relationships with tumor recurrence and resistance to adjuvant chemotherapy
68. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer
69. Chemotherapy targeted to hormone receptors on tumors
70. Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status
71. The relationship between cyclooxygenase-2 expression and colorectal cancer
72. Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac
73. Bax expression decreases significantly from primary tumor to metastasis in colorectal cancer